Warren Buffett Sells Apple Stock and Buys a Brand New Stock Up 5,600% in 30 Years

Warren Buffett's Berkshire Hathaway significantly reduced its Apple (AAPL) stake in Q2, selling 20 million shares amidst concerns over the tech giant's stalled innovation, disappointing AI execution, and a high valuation relative to projected growth, though it remains Berkshire's largest holding. Concurrently, Berkshire initiated a new position in UnitedHealth Group (UNH), a diversified healthcare company whose stock is trading 42% below its peak due to unexpected medical cost increases, an 18% earnings decline in H1 2025, and multiple ongoing Justice Department and FTC probes into its business practices.

Analysis

Berkshire Hathaway significantly reduced its Apple (AAPL) stake in Q2, selling 20 million shares and totaling 625 million shares sold since late 2023, representing 70% of its initial position. Despite this, AAPL remains Berkshire's largest holding. Concurrently, Berkshire initiated a new position in UnitedHealth Group (UNH), a diversified healthcare company trading 42% below its record high.

Apple faces scrutiny over its innovation pipeline and artificial intelligence (AI) execution, with "Apple Intelligence" failing to catalyze upgrades and a key Siri feature delayed until H1 2026. An eight-year innovation drought since 2017, combined with a rich 40x earnings valuation against 10% projected annual growth, raises significant concerns.

UnitedHealth Group is grappling with significant financial and regulatory headwinds. It underestimated 2025 expenses by $6.5 billion due to higher medical costs, leading to an 18% earnings decline in H1 2025. The company also faces multiple Justice Department probes regarding antitrust and alleged inflated Medicare Advantage billings, alongside an FTC lawsuit.

Overall sentiment for both stocks is strongly negative, with UNH exhibiting a slightly more negative per-ticker sentiment (-0.8) compared to AAPL (-0.6). These insider transactions, alongside fundamental concerns regarding innovation, valuation, rising costs, and extensive legal challenges, underscore a cautious outlook.

Key Decisions for Investors

• Investors should exercise caution with Apple (AAPL) given its rich 40x earnings valuation, eight-year innovation drought, and delayed AI catalysts, considering avoiding new positions until valuation becomes more reasonable.
• For UnitedHealth Group (UNH), investors should closely monitor the impact of $6.5 billion in underestimated expenses, the 18% earnings decline, and multiple ongoing Justice Department and FTC probes before considering new investments.
• Review portfolio exposure to companies exhibiting similar innovation stagnation or facing extensive regulatory and legal challenges, as these factors can significantly impact long-term performance.